Navigation Links
Gladstone and Lundbeck collaborate to study neurovascular disease
Date:7/21/2010

The Gladstone Institutes and the international pharmaceutical company H. Lundbeck A/S have announced a collaborative research agreement to study and identify therapeutic candidates for neurological diseases. The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD, and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging at the Gladstone Institute of Neurological Disease.

Dr. Akassoglou's pioneering research on blood proteins identified novel targets for therapeutic intervention in neurological diseases. Dr. Akassoglou has also developed imaging techniques to study neurovascular diseases in vivo, which will enable a better understanding of the origins and progress of these diseases, and thus find more practical strategies for disease detection and treatment.

"Our research on the role of blood proteins in brain functions has identified new targets for therapeutic intervention in multiple sclerosis and other neurological diseases," said Dr. Akassoglou. "Collaborating with the outstanding scientists at Lundbeck, offers great hope for discovering what triggers these diseases and developing novel therapeutic agents."

"Through its basic research into the origins of neurological disease, Gladstone has built an impressive knowledge into potential strategies and targets for treating devastating neurological diseases, such as multiple sclerosis and Alzheimer's disease," said Peter Hngaard Andersen, Executive Vice President of Research, H. Lundbeck A/S. "We are looking forward to applying new imaging technologies to help evaluate and translate these discoveries into patient benefits."

"Lundbeck is a truly visionary company with a well-focused strategy for building a pipeline to treat neurological disease," said Gladstone president R. Sanders Williams, MD. "We are enthusiastic about the potential of this important collaboration."

While the Gladstone Institutes was established in 1979 as an independent, non-profit biomedical research institute, the Gladstone Center for Translational Research was established in 2006 to move its most advanced discoveries into preclinical development with biotechnology and pharmaceutical industry partners. Examples of such collaborations include a research program with Merck on Alzheimer's disease and projects with Gilead and JT Pharma on HIV. The Taube-Koret Center for Huntington's Disease Research is another component that focuses on developing disease models and drug targets for Huntington's and related neurodegenerative disease.


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related medicine news :

1. Gladstones Robert Mahley to receive Research!America advocacy award
2. Gladstones Deepak Srivastava elected to the American Academy of Arts and Sciences
3. Hope Phones, IntraHealth and FrontlineSMS:Medic Collaborate on Phone Donation Campaign to Support Health Workers in Africa
4. The Advisory Board Company and HIMSS Analytics to Collaborate to Solve Health Care IT Challenges
5. Philips Collaborates with Microsoft to Enhance Healthcare Efficiencies and Productivity
6. FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs
7. Eisner USA, LLC Collaborates with Surgical Review Corp to Provide Innovative Bariatric Devices to Bariatric Surgery Center of Excellence (BSCOE) Participants
8. Doctors must collaborate so that patients get full benefit of tamoxifen treatment
9. PeopleStreme Collaborates with SkillSoft for Learning Management Content
10. BCS Global and Iformata Sign Agreement to Collaborate on the PSVN Initiative to Deliver B2B Video Communications
11. Two Hand Therapy Organizations Collaborate on Jam-Packed Educational Weekend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage ... Intercontinental Time Square, New York. , The program will be led by ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education Partners’ ... the field must first improve teacher preparation program design. It then asserts that ... that decades of input- and outcome-based research has failed to improve teacher education. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield ... Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, and ... estate valuation industry for more than 40 years. , “Ruel is a great ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, ... a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey and ... emphasizes the fact that medication IS NOT the only solution to deal with thyroid ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017   Dynatronics ... today the appointment of Cynthia L. McHenry ... will be responsible for leading Dynatronics manufacturing, distribution, ... will report to Dynatronics, CEO Kelvyn H. ... concludes an extensive search process conducted by the ...
(Date:3/29/2017)... , March 29, 2017 Neurim ... which Exeltis will obtain exclusive marketing rights for Neurim,s new Rx ... ... drug targeted to treat sleep disorders in children with Autism Spectrum ... first sleep medication approved for children. The collaboration with ...
(Date:3/29/2017)... SHELTON, Connecticut , March 29, 2017 /PRNewswire/ ... cybersecurity company Sectra (STO: SECT B) ... (UPHS) will install Sectra PACS in their healthcare ... and the Epic EMR, will enable access and ... clinical pathway. Additionally, UPHS and Sectra will enter ...
Breaking Medicine Technology: